The U.S. Food and Drug Administration (FDA) approved Eptinezumab on February 21, 2020.

The U.S. Food and Drug Administration (FDA) approved Palforzia on January 31, 2020.

The U.S. Food and Drug Administration (FDA) approved Trijardy XR on January 27, 2020, for the treatment of type 2 diabetes in adults.

The U.S. Food and Drug Administration (FDA) approved Tazemetostat on January 23, 2020, for the treatment of specific types of advanced cancers, specifically epithelioid sarcoma and follicular lymphoma.

The U.S. Food and Drug Administration (FDA) approved Teprotumumab on January 21, 2020, for the treatment of Thyroid Eye Disease (TED), also known as Graves' Eye Disease.

The U.S. Food and Drug Administration (FDA) approved Avapritinib on January 9, 2020, for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

The U.S. Food and Drug Administration (FDA) approved Ubrogepant on December 23, 2019.

The U.S. Food and Drug Administration (FDA) first approved Enhertu on December 20, 2019, for the treatment of HER2-positive breast cancer.

The U.S. Food and Drug Administration (FDA) approved Caplyta on December 20, 2019, for the treatment of schizophrenia in adults.

The U.S. Food and Drug Administration (FDA) approved Dayvigo on December 20, 2019, for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults.

The U.S. Food and Drug Administration (FDA) granted approval to Padcev on December 18, 2019, for the treatment of adults with locally advanced or metastatic urothelial cancer, a common type of bladder cancer.

The U.S. Food and Drug Administration (FDA) approved golodirsen on December 12, 2019, for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.